Antibody Type: Rabbit Monoclonal

Application: WB, FCM, ICC/IF, IP

Reactivity: Human

Rabbit IgG

3D707

Human

1. Immunofluorescence staining of Human CRABP2 in MCF7 cells. Cells were fixed with 4% PFA, permeabilzed with 1% Triton X-100 in PBS, blocked with 10% serum, and incubated with Rabbit anti-Human CRABP2 monoclonal antibody (1:300) at 4°C overnight. Then cells were stained with the Alexa Fluor® 488-conjugated Goat Anti-rabbit IgG secondary antibody (green) and counterstained with DAPI (blue). Positive staining was localized to cytoplasm.
2. Anti-CRABP2 rabbit monoclonal antibody at 1:500 dilution.
-Lane A: 293T Whole Cell Lysate.
-Lane B: MCF7 Whole Cell lysate.
-Lysates/proteins at 30 μg per lane.
-Secondary
-Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution.
-Developed using the Odyssey technique.
-Performed under reducing conditions.
-Predicted band size:16 kDa.
-Observed band size:14 kDa.
3. CRABP2 was immunoprecipitated using:
-Lane A:0.5 mg 293T Whole Cell Lysate.
-Lane B:0.5 mg Raji Whole Cell Lysate
-0.5 µL anti-CRABP2 rabbit monoclonal antibody and 60 μg of Immunomagnetic beads Protein G.
-Primary antibody:
-Anti-CRABP2 rabbit monoclonal antibody, at 1:500 dilution.
-Secondary antibody:
-Dylight 800-labeled antibody to rabbit IgG (H+L), at 1:5000 dilution.
-Developed using the odyssey technique.
-Performed under reducing conditions.
-Predicted band size: 16 kDa.
-Observed band size: 16 kDa.
4. Flow cytometric analysis of Human CRABP2 expression on MCF-7 cells. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human CRABP2, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.

WB,FCM,ICC/IF,IP

WB: 1:500-1:1000; ICC-IF: 1:100-1:500; FCM: 1:100-1:500; IP: 0.1-0.5 μL/mg of lysate

Monoclonal

Unconjugated

PE

2

Recombinant Protein: Human CRABP2 protein (TMPY-01549)

Human